PMID- 19194451
OWN - NLM
STAT- MEDLINE
DCOM- 20090626
LR  - 20171116
IS  - 1476-5489 (Electronic)
IS  - 0955-9930 (Linking)
VI  - 21
IP  - 2
DP  - 2009 Mar-Apr
TI  - Safety and efficacy of the simultaneous administration of udenafil and an 
      alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS.
PG  - 122-8
LID - 10.1038/ijir.2009.2 [doi]
AB  - We evaluated the clinical efficacy and safety of administering udenafil 
      (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) 
      in patients with comorbid benign prostatic hyperplasia (BPH) and erectile 
      dysfunction (ED). One hundred and twenty patients who had been undergoing stable 
      alpha-blocker therapy for BPH were enrolled in this trial and they were 
      administered 100 mg udenafil for 8 weeks. Changes in blood pressure (BP), heart 
      rate (HR), the international prostatic symptom score (IPSS) and the international 
      index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no 
      significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) 
      and ED improved significantly compared with baseline (IPSS 14.3-11.5, IIEF-5 
      11.95-18.32, P<0.05). Most patients were tolerant to the treatment and there was 
      no evidence of additional side effects related to coadministration. The 
      coadministration of udenafil and an alpha-blocker in patients with comorbid BPH 
      and ED was safe and gave significant improvements in both LUTS and ED.
FAU - Chung, B H
AU  - Chung BH
AD  - Department of Urology, Yonsei University Health System, Seoul, Korea.
FAU - Lee, J Y
AU  - Lee JY
FAU - Lee, S H
AU  - Lee SH
FAU - Yoo, S J
AU  - Yoo SJ
FAU - Lee, S W
AU  - Lee SW
FAU - Oh, C Y
AU  - Oh CY
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090205
PL  - England
TA  - Int J Impot Res
JT  - International journal of impotence research
JID - 9007383
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - EC 3.1.4.35 (Cyclic Nucleotide Phosphodiesterases, Type 5)
RN  - L5IB4XLY36 (udenafil)
SB  - IM
MH  - Adrenergic alpha-Antagonists/adverse effects/*therapeutic use
MH  - Aged
MH  - Blood Pressure/drug effects/physiology
MH  - Cyclic Nucleotide Phosphodiesterases, Type 5/metabolism
MH  - Drug Therapy, Combination
MH  - Erectile Dysfunction/*complications/*drug therapy
MH  - Heart Rate/drug effects/physiology
MH  - Humans
MH  - Hypertension/complications/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Phosphodiesterase Inhibitors/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Prostatic Hyperplasia/*complications
MH  - Pyrimidines/adverse effects/*therapeutic use
MH  - Sulfonamides
MH  - Urologic Diseases/*complications
EDAT- 2009/02/06 09:00
MHDA- 2009/06/27 09:00
CRDT- 2009/02/06 09:00
PHST- 2009/02/06 09:00 [entrez]
PHST- 2009/02/06 09:00 [pubmed]
PHST- 2009/06/27 09:00 [medline]
AID - ijir20092 [pii]
AID - 10.1038/ijir.2009.2 [doi]
PST - ppublish
SO  - Int J Impot Res. 2009 Mar-Apr;21(2):122-8. doi: 10.1038/ijir.2009.2. Epub 2009 
      Feb 5.